MaxCyte Common Stock Total Equity from 2010 to 2025
| MXCT Stock | USD 2.82 0.04 1.44% |
Common Stock Total Equity | First Reported 2010-12-31 | Previous Quarter 1.2 M | Current Value 807.8 K | Quarterly Volatility 243.9 K |
Check MaxCyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among MaxCyte's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5 M, Interest Expense of 138.6 K or Selling General Administrative of 31.2 M, as well as many indicators such as Price To Sales Ratio of 10.73, Dividend Yield of 0.0 or PTB Ratio of 2.22. MaxCyte financial statements analysis is a perfect complement when working with MaxCyte Valuation or Volatility modules.
MaxCyte | Common Stock Total Equity |
Latest MaxCyte's Common Stock Total Equity Growth Pattern
Below is the plot of the Common Stock Total Equity of MaxCyte over the last few years. It is the total value of common stock equity held by shareholders, representing their ownership interest in the company. MaxCyte's Common Stock Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in MaxCyte's overall financial position and show how it may be relating to other accounts over time.
| Common Stock Total Equity | 10 Years Trend |
|
Common Stock Total Equity |
| Timeline |
MaxCyte Common Stock Total Equity Regression Statistics
| Arithmetic Mean | 686,155 | |
| Geometric Mean | 650,853 | |
| Coefficient Of Variation | 35.54 | |
| Mean Deviation | 212,782 | |
| Median | 513,300 | |
| Standard Deviation | 243,855 | |
| Sample Variance | 59.5B | |
| Range | 668.6K | |
| R-Value | 0.82 | |
| Mean Square Error | 21B | |
| R-Squared | 0.67 | |
| Significance | 0.0001 | |
| Slope | 41,938 | |
| Total Sum of Squares | 892B |
MaxCyte Common Stock Total Equity History
About MaxCyte Financial Statements
MaxCyte shareholders use historical fundamental indicators, such as Common Stock Total Equity, to determine how well the company is positioned to perform in the future. Although MaxCyte investors may analyze each financial statement separately, they are all interrelated. The changes in MaxCyte's assets and liabilities, for example, are also reflected in the revenues and expenses on on MaxCyte's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Common Stock Total Equity | 1.2 M | 807.8 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.